Blurbs

B.Riley Financial Remains a Buy on Altimmune (ALT)

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALTResearch Report) today and set a price target of $26.00. The company’s shares closed today at $10.79.

According to TipRanks, Mamtani is an analyst with an average return of -30.0% and a 21.94% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Agenus.

Altimmune has an analyst consensus of Strong Buy, with a price target consensus of $28.83, implying a 167.19% upside from current levels. In a report released today, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $20.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $23.49 and a one-year low of $3.83. Currently, Altimmune has an average volume of 2.33M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.

Read More on ALT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More